The mechanism of acquisition of tumorigenic properties by somatic cells at the onset of cancer and later during relapse is a question of paramount importance in cancer biology. We have recently discovered a Muscleblind like-1 (MBNL1)-driven alternative-splicing mediated mechanism of tumorigenic de-differentiation that is associated with poor prognosis, relapse and metastasis in common cancer types.
CITATION STYLE
Ray, D., & Epstein, D. M. (2020). Tumorigenic de-differentiation: the alternative splicing way. Molecular and Cellular Oncology, 7(6). https://doi.org/10.1080/23723556.2020.1809959
Mendeley helps you to discover research relevant for your work.